Eli Lilly and Company (LLY80)
Thailand Exchange · Thailand · prices in THB · close of 22 Oct 2026
Key indicators
| Last close | THB 2.140 |
|---|---|
| 52-week range | 1.310 – 2.180 |
| Return, 1 month / 3 months | +10.9% / +8.8% |
| Return, 1 year / 3 years | +61.9% / – |
| Trend | Uptrend |
| RSI (14) | 68 |
| Volatility (1 year) | 37.4% |
| Worst drawdown (1 year) | -22.0% |
| Average daily value traded | 10.95M THB |
| Dividend yield | 17.0% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Eli Lilly and Company is a pharmaceutical company based in Indianapolis in the United States. It researches, develops and makes prescription medicines for people with diabetes, cancer, mental health conditions and immune system disorders. Its products include insulin and other diabetes treatments, antidepressants and antipsychotic medicines, and therapies for serious illnesses. It supplies hospitals, clinics, doctors and patients, mainly in the United States and other markets around the world, through its own sales teams and distribution partners.
The shares are listed on the Thailand Exchange in Thailand under the code LLY80, and the price on this page is in Thai baht (THB). Our dividend records, which start in 2019, show payments in 2 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Eli Lilly and Company (LLY80) trades on the Thailand Exchange in Thailand. It last closed at THB 2.140 on 22 October 2026.
Its price-based Market X-Ray is 75 out of 100 (a strong price profile), ranking 104 of 1,349 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 61.9% and over the last three months it rose 8.8%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Thailand Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 86 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 21.0% | ||
| From 52-week high | 0.0% | ||
| Momentum | 86 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 8.8% | ||
| 6-month return | 46.0% | ||
| 12-month return, skipping the last month | 46.0% | ||
| Stability (higher is calmer) | 56 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 37.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -22.0% | ||
| Liquidity | 84 · Strong | Trades actively. | |
| Average daily value traded | 10.95M THB | ||
| Zero-volume days | 3.3% | ||
| Income | 57 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 17.0% | ||
| Years with dividends | 2 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | +3.9% |
|---|---|
| 1 month | +10.9% |
| 3 months | +8.8% |
| 6 months | +46.0% |
| 1 year | +61.9% |
| 3 years | – |
| 5 years | – |
Signals
| 50-day / 200-day average | 1.970 / 1.768 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | Yes |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.057 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 14 Aug 2026 | USD 0.0028 |
| 15 May 2026 | USD 0.0028 |
| 13 Feb 2026 | USD 0.0027 |
| 14 Nov 2025 | USD 0.0024 |
| 15 Aug 2025 | USD 0.0025 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Thailand Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.